Skip to main content

Advertisement

Table 2 Patient characteristics (all patients, N = 421)

From: Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies

Demographics  
   Boys, N (%) 338 (80.3)
   Girls, N (%) 83 (19.7)
   Age [years], mean (± SD) 11.1 (2.7)
ADHD subtype, N (%)  
   Combined 278 (66.0)
   predominantly inattentive 124 (29.5)
   predominantly hyperactive-impulsive 6 (1.4)
   ADHD, not otherwise specified 13 (3.1)
Most frequent psychiatric comorbidities, N (%)  
   Conduct disorder 83 (19.7)
   Oppositional defiant disorder 74 (17.6)
   Enuresis 18 (4.3)
   Emotional disorder of childhood 11 (2.6)
   Tic disorder 10 (2.4)
   Depression 6 (1.4)
   Depressed mood 5 (1.2)
Baseline disease characteristics, mean (± SD)  
   ADHD-RS, total score 32.6 (10.9)
   CGI-Severity (of ADHD) 5.0 (0.8)
   WREMB-R, total score 18.0 (7.0)
   GIPD, total score patient-rated 13.1 (5.8)
   GIPD, total score parent-rated 18.6 (6.1)
   GIPD, total score physician-rated 20.3 (5.9)
  1. Abbreviations: ADHD = Attention deficit/hyperactivity disorder, ADHD-RS = ADHD Rating Scale (parent-rated, investigator-administered and scored), CGI-Severity = Clinical Global Impression, Severity, GIPD = Global Impression of perceived difficulties, SD = standard deviation, WREMB-R = Weekly Ratings of Evening and Morning Behavior-Revised